Business Description
AVEO Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0535881090
Share Class Description:
STU:VPA1: Ordinary SharesDescription
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2 | |||||
| Equity-to-Asset | 0.29 | |||||
| Debt-to-Equity | 1.34 | |||||
| Debt-to-EBITDA | -1.59 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -4.48 | |||||
| Beneish M-Score | -0.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 46.2 | |||||
| 3-Year EBITDA Growth Rate | -84.5 | |||||
| 3-Year EPS without NRI Growth Rate | 5.5 | |||||
| 3-Year FCF Growth Rate | 2.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 106.43 | |||||
| 12-1 Month Momentum % | 317.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.37 | |||||
| Quick Ratio | 2.35 | |||||
| Cash Ratio | 1.82 | |||||
| Days Inventory | 44.63 | |||||
| Days Sales Outstanding | 50.35 | |||||
| Days Payable | 122.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -39.7 | |||||
| Shareholder Yield % | -3.44 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.81 | |||||
| Operating Margin % | -25.97 | |||||
| Net Margin % | -30.79 | |||||
| FCF Margin % | -22.81 | |||||
| ROE % | -75.04 | |||||
| ROA % | -28.36 | |||||
| ROIC % | -275.23 | |||||
| ROC (Joel Greenblatt) % | -5370.33 | |||||
| ROCE % | -32.44 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 48.38 | |||||
| PS Ratio | 5.49 | |||||
| PB Ratio | 18.01 | |||||
| Price-to-Tangible-Book | 18.15 | |||||
| EV-to-EBIT | -19.76 | |||||
| EV-to-EBITDA | -19.81 | |||||
| EV-to-Revenue | 5.12 | |||||
| EV-to-Forward-Revenue | 2.98 | |||||
| EV-to-FCF | -21.3 | |||||
| Price-to-Median-PS-Value | 0.71 | |||||
| Price-to-Net-Current-Asset-Value | 18.39 | |||||
| Price-to-Net-Cash | 106.12 | |||||
| Earnings Yield (Greenblatt) % | -5.06 | |||||
| FCF Yield % | -4.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AVEO Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 89.303 | ||
| EPS (TTM) (€) | -0.776 | ||
| Beta | 0 | ||
| Volatility % | 124.44 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.1375 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 317.31 | ||
| 52-Week Range (€) | 2.742 - 15.07 | ||
| Shares Outstanding (Mil) | 34.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AVEO Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AVEO Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
AVEO Pharmaceuticals Inc Frequently Asked Questions
What is AVEO Pharmaceuticals Inc(STU:VPA1)'s stock price today?
The current price of STU:VPA1 is €13.80. The 52 week high of STU:VPA1 is €15.07 and 52 week low is €2.74.
When is next earnings date of AVEO Pharmaceuticals Inc(STU:VPA1)?
The next earnings date of AVEO Pharmaceuticals Inc(STU:VPA1) is 2024-05-05 Est..
Does AVEO Pharmaceuticals Inc(STU:VPA1) pay dividends? If so, how much?
AVEO Pharmaceuticals Inc(STU:VPA1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers